| Sep 1, 2024 | CSA Medical | $53.0M Series D | TVM Capital, Yonjin Capital | Ascension Ventures, SV Health Investors |
| Apr 22, 2024 | Smart Reporting | $24.5M Series C | Hubert Birner | Ann-Kristin Achleitner, Charlie Songhurst, Lutz Finger, Rolf Christof Dienst, Sean Mullaney, Wolfgang Reitzle |
| Feb 1, 2024 | Vektor Medical | $25.0M Series A | Solas BioVentures, Jean-Luc Marengo | — |
| Jan 31, 2024 | Myo | $8.7M Series A | Sascha Berger | Agaplesion, Axel Springer Plug and Play, BonVenture, Capacura, Carpediem Capital, Mountain Partners, Round Hill Ventures, Think.Health Ventures, Stefan Fischer, Twip |
| Mar 3, 2021 | Access Vascular | $15.0M Series B | Alexandra MacLean | — |
| Mar 5, 2019 | Emovi | $11.3M Series C | Dr. Luc Marengere | Desjardins Capital, StandUp Ventures |
| May 2, 2018 | Rapid Micro Biosystems | $60.0M Other Equity | Jeff Schwartz, Fares Zahir | Asahi Kasei Medical, Longitude Capital, Quaker Partners |
| Jun 16, 2017 | Centogene | $28.0M Series A | Hubert Birner | Eric Souêtre, CIC Capital, Guido Prehn |
| May 10, 2016 | Acer Therapeutics | $8.2M Series B | Cynthia Lavoie | Bukwang Pharmaceutical |
| Jul 27, 2015 | leon nanodrugs | $20.6M Series A | Hubert Birner | Albany Private Equity Holding, CD-Venture, Gerhard Ries, James C. Gale |
| Apr 1, 2015 | Rapid Micro Biosystems | $25.0M Series C | — | Apollo Health Ventures, Shawn Lu, Kleiner Perkins, Longitude Capital, Quaker Partners, Richard King Mellon Foundation, Fred Cohen |
| Jan 1, 2015 | CoLucid Pharmaceuticals | $37.0M Series C | Dr. Luc Marengere | Cincy Tech, Domain Associates, Kleiner Perkins, Versant Ventures, Auriga Partners, Care Capital, Martin Edwards, Pappas Ventures, Pearl Street Venture Funds, Triathlon Medical Ventures |
| May 16, 2014 | Proteon Therapeutics | $45.0M Series D | Tim Haines | Bessemer Venture Partners, Deerfield Management, Devon Park Bioventures, Intersouth Partners, MPM Capital, Dmitry Kobyzev, Ph.D., Prism VentureWorks, Skyline Ventures, Vectis Healthcare and Life Sciences Fund |
| Nov 20, 2013 | Argos Therapeutics | $17.5M Series E Extension | — | Aurora Funds, Forbion, Green Cross Holdings, Intersouth Partners, Lumira Ventures, Morningside, Pharmstandard International |
| Oct 1, 2013 | F-Star Therapeutics | $9.0M Star Therapeutics - Series A | — | Atlas Venture, INKEF Capital, Aescap Venture, MP Healthcare Venture Management, MS Ventures, SR One |
| Aug 28, 2013 | Argos Therapeutics | $42.5M Series E | Alexandr Shuster | Aurora Funds, Forbion, Green Cross Holdings, Intersouth Partners, Lumira Ventures, Morningside |
| Jun 1, 2013 | Rapid Micro Biosystems | $33.0M Series B | David Hirsch, Mark Braganza | Apollo Health Ventures, Kleiner Perkins, Quaker Partners |
| Jul 1, 2012 | Bluebird Bio | $60.0M Series D | — | ARCH Venture Partners, Third Rock Ventures, Howie Furst, Forbion, RA Capital Management, Ramius Capital Group, Shire |
| Apr 24, 2012 | Argos Therapeutics | $25.0M Series D | Forbion | Aurora Funds, Intersouth Partners, Lumira Ventures, Morningside |
| Jan 4, 2012 | Vivoryon Therapeutics | $19.4M Other Equity | — | BB Biotech, Biogen Idec New Ventures, GoodVent, HBM Healthcare Investments, LSP, Wellington Management |
| Apr 20, 2011 | Bluebird Bio | $30.0M Other Equity II | — | Steven Gillis, Easton Capital, Forbion, Third Rock Ventures |
| Apr 13, 2011 | F-Star Therapeutics | $21.7M Star Therapeutics - Other Equity | Deborah Harland | Aescap Venture, Atlas Venture, MP Healthcare Venture Management, M Ventures, Novo Ventures, Axel Polack |
| Oct 21, 2010 | Abionyx Pharma | $14.0M Series C | IRDI Capital Investissement | Alta Partners, Daiwa Corporate Investment, EDF Ventures, HealthCap, OrbiMed, Sofinnova Partners, Strategic Investment Fund |
| Oct 12, 2010 | TME Pharma | $2.8M Series D Extension | — | Sofinnova Partners, CD-Venture, DEWB, Dieckell Group, IBB Ventures, IBG Sachsen-Anhalt, NGN Capital, Oppenheim Asset Management Services, Seventure Partners, The Dow Chemical Company |
| Aug 20, 2010 | Anchor Therapeutics | $10.0M Series B | HealthCare Ventures, Novartis, TVM Capital | — |
